Acute Pharyngitis Market

Market Overview:

The 7 major acute pharyngitis markets reached a value of US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 4.7% during 2024-2034.

The acute pharyngitis market has been comprehensively analyzed in IMARC's new report titled "Acute Pharyngitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute pharyngitis, commonly known as a sore throat, refers to an inflammation of the pharynx, the area at the back of the throat. This disorder can be caused by viral or bacterial infections, environmental factors, or irritants. The condition is characterized by symptoms, such as soreness, scratchiness, or pain in the throat, especially when swallowing. It often accompanies indications like coughing, sneezing, a runny nose, and occasionally, fever. The diagnosis of acute pharyngitis involves a combination of clinical evaluation and, in some cases, diagnostic tests. The healthcare providers typically begin by examining the patient's throat for redness, swelling, or pus on the tonsils. They may also inquire about the duration and severity of the symptoms. If a bacterial infection is suspected, a rapid strep test might be performed to detect the presence of Streptococcus bacteria. In some instances, a throat culture might be sent to a laboratory for more accurate identification of the causative agent.

The rising cases of bacterial and viral infections, in which the pathogen invades the mucosal tissues of the pharynx directly, causing inflammation and irritation, are primarily driving the acute pharyngitis market. In addition to this, the inflating utilization of effective antibiotics like penicillin, cephalosporins, macrolides, etc., to combat bacterial cases of the condition is also creating a positive outlook for the market. These therapeutic agents work by inhibiting the synthesis of bacterial cell walls and preventing bacterial replication and proliferation in patients. Moreover, the widespread adoption of symptomatic treatments, such as analgesics and throat lozenges, which provide relief from pain and inflammation, is further fueling the market growth. Apart from this, the increasing awareness and utilization of salt-water gargling, humidifiers, and hydration therapies to improve treatment outcomes in individuals suffering from the disorder are acting as another significant growth-inducing factor. Additionally, the escalating demand for rapid antigen tests, since they are specifically designed to diagnose streptococcal pharyngitis promptly, is also augmenting the market growth. Furthermore, numerous advancements in immunization against some causative pathogens, including the influenza virus and Streptococcus pneumoniae, to prevent the contraction of the disease are expected to drive the acute pharyngitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the acute pharyngitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for acute pharyngitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute pharyngitis market in any manner.

Key Highlights:

• Acute pharyngitis is the cause of around 12 million annual ambulatory care visits in the United States.
• It ranks among the top twenty most prevalent primary diagnostic groups.
• Among adults, the majority of cases of acute pharyngitis occur before age 40, and the incidence decreases thereafter.
• The incidence peaks in infancy and adolescence, with almost half of all cases occurring before the age of 18.
• Prolonged severely cold weather occurrences rapidly elevated emergency visit risk for acute pharyngitis by more than three times compared to median temperatures.

Drugs:

Azithromycin (Zithromax) is a macrolide antibiotic. It is used to treat a variety of illnesses in children and adults, including acute pharyngitis. Zithromax is taken orally once a day. Treatment typically lasts 3 to 5 days, depending on the form of illness.

Suprax is a cephalosporin antibiotic used to treat susceptible infections, such as pharyngitis. Suprax is already available as 100mg/5mL and 200mg/5mL oral solutions, 400mg pills, and 100mg and 200mg chewable tablets.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acute pharyngitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acute pharyngitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acute pharyngitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the acute pharyngitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the acute pharyngitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the acute pharyngitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of acute pharyngitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acute pharyngitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acute pharyngitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with acute pharyngitis across the seven major markets?
• What is the size of the acute pharyngitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of acute pharyngitis?
• What will be the growth rate of patients across the seven major markets?
   

Acute Pharyngitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acute pharyngitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute pharyngitis market?
• What are the key regulatory events related to the acute pharyngitis market?
• What is the structure of clinical trial landscape by status related to the acute pharyngitis market?
• What is the structure of clinical trial landscape by phase related to the acute pharyngitis market?
• What is the structure of clinical trial landscape by route of administration related to the acute pharyngitis market?